Meningioma Pipeline Analysis 2018 – Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments.
Meningioma Pipeline Analysis report covers 13 drugs currently in different phases of development. Meningioma is the tumor that develops in the layer called meninges which protect the brain and spinal cord. These are the most common form of tumors, slow growing and are mostly benign. When small in size meningioma may not cause any symptoms, however, larger size meningioma increase the pressure inside the skull and causes problems like headache, nausea and vomiting and seizures due to electrical disturbances inside the brain. Most of the meningiomas are treated through surgeries. Radiation therapy may also be used to shrink the tumor, or post-surgery to treat small remainders of tumor or if the patient is too ill to undergo surgery.
The report provides meningiomas treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are AstraZeneca, Boehringer Ingelheim GmBH, Eli Lilly and Company, Lixte Biotechnology Holdings, Inc. and Novocure among others.
Scope:
By Company
By Phase
By Molecule Type
By Region
By Route of Administration